Biocryst Pharmaceuticals reported $-17445000 in Operating Profit for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Profit Change
DBV Technologies DBVT:US USD -18020000 5.8M
Alnylam Pharmaceuticals ALNY:US USD -334626000 142.94M
Biocryst Pharmaceuticals BCRX:US USD -17445000 17.28M
Chugai Pharma 4519:JP JPY 96.89B 3.05B
Daiichi Sankyo 4568:JP JPY 61.2B 26.82B
Enanta Pharmaceuticals ENTA:US USD -27048000 5.49M
Gilead Sciences GILD:US USD 2.84B 808M
GlaxoSmithKline GSK:LN GBP 1.19B 110M
Glaxosmithkline GSK:US GBP 1.19B 110M
Intra Cellular Therapies ITCI:US USD -55629000 32.29M
IONIS PHARMACEUT IONS:US USD -59154000 26.36M
Karyopharm Therapeutics KPTI:US USD -30839000 12.07M
Mirati Therapeutics MRTX:US USD -186443000 9.24M
Neurocrine Biosciences NBIX:US USD 87.8M 103.1M
Novavax NVAX:US USD -127189000 355.77M
Ptc Therapeutics PTCT:US USD -68187000 24.17M
Regeneron Pharmaceuticals REGN:US USD 1.22B 113.8M
Sarepta Therapeutics SRPT:US USD -256796000 45.66M
Ultragenyx Pharmaceutical RARE:US USD -225066000 83.47M
Vertex Pharmaceuticals VRTX:US USD 1.13B 20.4M
YTE INCY:US USD 138.38M 116.06M